Enasidenib Mesylate 100 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 100 mg

Reference Brands: Idhifa (USA)

Category: Oncology Cancer Care

Enasidenib Mesylate is a Oncology Cancer Care product available as Tablets in strengths 100 mg. It corresponds to the reference brand Idhifa (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Enasidenib mesylate is a targeted anticancer therapy used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who carry a specific mutation in the isocitrate dehydrogenase-2 (IDH2) gene. It is prescribed when the disease has returned or has not responded adequately to prior treatment and is administered under specialist oncology care. In addition to its approved indication in AML, enasidenib mesylate is also being studied for potential use in other cancer types.

Mechanistically, enasidenib mesylate works by selectively inhibiting the abnormal IDH2 enzyme produced by the mutated gene. This inhibition helps reduce the production of oncometabolites that interfere with normal blood cell differentiation. Rather than directly killing cancer cells, the drug promotes the maturation of malignant cells into more normal forms, thereby slowing disease progression.

Enasidenib mesylate is classified as an enzyme inhibitor and is available as an oral tablet for once-daily administration. Commonly reported side effects include nausea, vomiting, diarrhea, reduced appetite, and elevated bilirubin levels. Due to potential risks to fetal and infant development, its use is not recommended during pregnancy or breastfeeding. Careful patient monitoring is essential throughout treatment.